KRYS   $113.28  -3.30% Market Closed

Krystal Biotech Inc
Last Events:

2023-08-09 Signal in MACD changed from bullish weakening to bearish reversal. Oscillator MACD is in the positive territory it crossed the signal line from the top and falls. These factors mean that the market confirms the end of the upward trend. Last signal: main and signal line crossing.

2023-08-09 Signal in RSI changed from bullish weakening to bearish. RSI indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: exit from the overbought zone.

2023-08-09 Signal in EMA50 changed from bullish reversal to bearish reversal. The price is trying to cross down the moving average line If the intersection will be successful, then a downside trend can be formed.

2023-08-09 Signal in EMA20 changed from bullish reversal to bearish reversal. The price is trying to cross down the moving average line If the intersection will be successful, then a downside trend can be formed.

2023-08-06 Signal in Stochastic changed from bearish reversal to bearish. The stochastic indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: down-crossing the middle level.

2023-08-05 Signal in Stochastic changed from bullish weakening to bearish reversal. The stochastic indicator is in the upper part of the neutral territory and left the overbought territory. These factors indicate that perhaps the upside trend is coming to an end price will probably head south Last signal: exit from the overbought zone.

2023-08-04 Signal in Stochastic changed from bullish to bullish weakening. The stochastic indicator is in overbought territory and it heading south. These factors indicate that perhaps the upside trend is coming to an end. Last signal: main and signal line crossing.

2023-08-04 Signal in MACD changed from bullish recovery to bullish weakening. Oscillator MACD is in the positive territory it's higher than the signal line and falls. These factors mean that the growing trend persists, but the growth rate is declining. Last signal: main and signal line crossing.


Current temperature: 4.32
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 10
Target Price Mean 151.40
Mean unverified/preliminary 151.40 / 151.40
Target Price Low / High 130.00 / 168.00
Median / STD DEV 153.50 / 11.79
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total ActivelyBuy ActivelyBuy ActivelyBuy
rsi ActivelyBuy None ActivelyBuy
macd None None None
stoch None None None
ma20 ActivelyBuy ActivelyBuy Sell
ma50 None None None
ma100 ActivelyBuy ActivelyBuy None
Candlestick PatternMarch 13, 2023 Doji - is formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.
ISIN US5011471027
ceo Mr. Krish S. Krishnan M.B.A., M.S.
Website https://www.krystalbio.com
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.